An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC. (FUTURE-SUPER)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04395989 |
Recruitment Status :
Active, not recruiting
First Posted : May 20, 2020
Last Update Posted : December 22, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
TNBC - Triple-Negative Breast Cancer | Drug: A1: Pyrotinib with nab-paclitaxel Drug: A2: nab-paclitaxel Drug: B1: everolimus with nab-paclitaxel Drug: B2: nab-paclitaxel Drug: C1: PD-1 with nab-paclitaxel and famitinib Drug: C2: nab-paclitaxel Drug: D1: VEGFR and nab-paclitaxel, with maintenance of VEGFR and capecitabine Drug: D2: nab-paclitaxel, with maintenance of capecitabine Drug: E1: everolimus with nab-paclitaxel Drug: E2: nab-paclitaxel | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 139 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | An Umbrella Trial Based on Molecular Pathway for Patients With Unresectable Locally Advanced or Metastatic Triple Negative Breast Cancer (FUTURE SUPER) |
Actual Study Start Date : | July 28, 2020 |
Actual Primary Completion Date : | May 31, 2023 |
Estimated Study Completion Date : | December 31, 2024 |
Arm | Intervention/treatment |
---|---|
Experimental: LAR-HER2mut
If patients were LAR subtype with HER2 gene activated mutation
|
Drug: A1: Pyrotinib with nab-paclitaxel
A1: pyrotinib(EGFR-TKI) 400mg po qd + nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle
Other Name: SHR1258 Drug: A2: nab-paclitaxel A2: nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle |
Experimental: LAR-PI3K/AKTmut
If patients were LAR subtype without HER2 gene activated mutation, but had PI3K/AKT/mTOR pathway mutation
|
Drug: B1: everolimus with nab-paclitaxel
B1: everolimus 10mg po qd + nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle Drug: B2: nab-paclitaxel B2: nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle |
Experimental: IM
If patients were IM subtype (CD8 positive T cell more than 10%)
|
Drug: C1: PD-1 with nab-paclitaxel and famitinib
C1: PD-1 antibody SHR1210 200mg d1,15 ivgtt + nab-paclitaxel 100mg/m2 d1,8,15 ivgtt + famitinib 20mg po qd, 4 weeks as a cycle
Other Names:
Drug: C2: nab-paclitaxel C2: nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle |
Experimental: BLIS/MES-PI3K/AKTWT
If patients were BLIS subtype or MES subtype without PI3K/AKT/mTOR pathway activation
|
Drug: D1: VEGFR and nab-paclitaxel, with maintenance of VEGFR and capecitabine
D1: VEGFR bevacizumab 10mg/kg d1,15 ivgtt + nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle. Capecitabine with bevacizumab maintenance if intolerable toxicity was observed with no progression. Capecitabine maintenance 1000mg/m2 po bid d1-d14 every 3 weeks and bevacizumab 10mg/kg d1,15 ivgtt every 4 weeks.
Other Name: Bevacizumab (BP102) Drug: D2: nab-paclitaxel, with maintenance of capecitabine D2: nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle. Capecitabine maintenance if intolerable toxicity was observed with no progression. Capecitabine maintenance 1000mg/m2 po bid d1-d14 every 3 weeks. |
Experimental: MES-PI3K/AKTmut
If patients were MES subtype and had PI3K/AKT/mTOR pathway activation
|
Drug: E1: everolimus with nab-paclitaxel
E1: everolimus 10mg po qd + nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle Drug: E2: nab-paclitaxel E2: nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle |
- Progression Free Survival (PFS) [ Time Frame: approximately 3 years ]Refers to the time between the patient's enrollment and any recorded tumor progression or death from any cause.
- Overall Survival (OS) [ Time Frame: approximately 3 years ]Refers to the period from the date of the first study dose to the date of death for any reason.
- Objective response rate (ORR) [ Time Frame: approximately 3 years ]Defined as the proportion of patients whose tumors shrink to a certain amount and remain for a certain period of time, including cases of CR and PR.
- Duration of Response (DoR) [ Time Frame: approximately 3 years ]Defined as the date from the first recording of tumor response (assessed according to RECIST 1.1) to the first recording of the objective progression of the tumor (assessed according to RECIST 1.1) or to the date of death for any reason, whichever occurs first.
- Disease Control Rate (DCR) [ Time Frame: approximately 3 years ]The proportion of subjects who received treatment and whose best overall response (BOR) was assessed as complete response (CR), partial response (PR) and stable disease (SD) ≥4 weeks according to RECIST1.1.
- Safety: Adverse Events (AE) [ Time Frame: approximately 3 years ]AE refers to any untoward medical occurrence in a study subject administered an investigational product which does not necessarily have a causal relationship with the treatment. AE is assessed according to the NCI-CTC AE 5.0.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 70 Years (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- ECOG Performance Status of 0-1
- Expected lifetime of not less than three months
- Metastatic or locally advanced, histologically documented TNBC (absence of HER2, ER, and PR expression)
- Cancer stage: recurrent or metastatic breast cancer; Local recurrence be confirmed by the researchers could not be radical resection.
- Adequate hematologic and end-organ function, laboratory test results, obtained within 14 days prior to initiation of study treatment.
- Measurable disease according to Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1)
- Patients had received no previous chemotherapy or targeted therapy for metastatic triple-negative breast cancer
- For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures as outlined for each specific treatment arm
- Have the cognitive ability to understand the protocol and be willing to participate and to be followed up.
Exclusion Criteria:
- Symptomatic, untreated, or actively progressing CNS metastases
- Active or history of autoimmune disease or immune deficiency
- Active hepatitis B or hepatitis C
- Significant cardiovascular disease
- History of malignancy other than breast cancer within 5 years prior to screening, with the exception of those with a negligible risk of metastasis or death
- Treatment with taxel-based chemotherapy within 6 months
- Treatment with chemotherapy, radiotherapy,immunotherapy or surgery (outpatient clinic surgery excluded)within3 weeks prior to initiation of study treatment.
- Pregnancy or breastfeeding, or intention of becoming pregnant during the study
- Previous received anti-VEGFR small molecule tyrosine kinase inhibitors (e.g. famitinib, sorafenib, Sunitinib, regorafenib, etc.) for treatment of the patients .
- A history of bleeding, any serious bleeding events.
- Important blood vessels around tumors has been infringed and high risk of bleeding.
- Long-term unhealing wound or incomplete healing of fracture
- Urine protein ≥2+ and 24h urine protein quantitative > 1 g.
- Arrhythmia for long-term use of anti-arrhythmic drugs and New York heart association class II or higher cardiac insufficiency
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04395989
China, Shanghai | |
Cancer Hospital Affiliated to Fudan University | |
Shanghai, Shanghai, China, 200032 |
Responsible Party: | Zhimin Shao, Director of General Surgery of Fudan Shanghai Cancer Center, Fudan University |
ClinicalTrials.gov Identifier: | NCT04395989 |
Other Study ID Numbers: |
SCHBCC-N031 |
First Posted: | May 20, 2020 Key Record Dates |
Last Update Posted: | December 22, 2023 |
Last Verified: | December 2023 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
TNBC Molecular Subtype Precision Treatment Umbrella Trial First Line |
Breast Neoplasms Triple Negative Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Paclitaxel Albumin-Bound Paclitaxel Capecitabine Everolimus Antineoplastic Agents, Phytogenic Antineoplastic Agents |
Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Antimetabolites, Antineoplastic Antimetabolites MTOR Inhibitors Protein Kinase Inhibitors Enzyme Inhibitors Immunosuppressive Agents Immunologic Factors |